Cite
Pagliarini S, Beatty S, Lipkova B, et al. A 2-Year, Phase IV, Multicentre, Observational Study of Ranibizumab 0.5 mg in Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice: The EPICOHORT Study. J Ophthalmol. 2014;2014:857148doi: 10.1155/2014/857148.
Pagliarini, S., Beatty, S., Lipkova, B., Perez-Salvador Garcia, E., Reynders, S., Gekkieva, M., Si Bouazza, A., & Pilz, S. (2014). A 2-Year, Phase IV, Multicentre, Observational Study of Ranibizumab 0.5 mg in Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice: The EPICOHORT Study. Journal of ophthalmology, 2014857148. https://doi.org/10.1155/2014/857148
Pagliarini, Sergio, et al. "A 2-Year, Phase IV, Multicentre, Observational Study of Ranibizumab 0.5 mg in Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice: The EPICOHORT Study." Journal of ophthalmology vol. 2014 (2014): 857148. doi: https://doi.org/10.1155/2014/857148
Pagliarini S, Beatty S, Lipkova B, Perez-Salvador Garcia E, Reynders S, Gekkieva M, Si Bouazza A, Pilz S. A 2-Year, Phase IV, Multicentre, Observational Study of Ranibizumab 0.5 mg in Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice: The EPICOHORT Study. J Ophthalmol. 2014;2014:857148. doi: 10.1155/2014/857148. Epub 2014 Apr 28. PMID: 24868458; PMCID: PMC4020221.
Copy
Download .nbib